phaseolotoxin: exotoxin from Pseudomonas sp.; cleavage of C terminal alanine and homoarginine from phaseolotoxin leaves octicidine
phaseolotoxin : A tripeptide resulting from the formal condensation of the carboxy group of N(5)-[amino(sulfoamino)phosphoryl]-L-ornithine with the N-terminal amino group of L-alanyl-L-arginine. A toxin produced by cultured Pseudomonas syringae, the causal agent of halo blight disease in bean plants.
ID Source | ID |
---|---|
PubMed CID | 9936860 |
MeSH ID | M0314460 |
Synonym |
---|
n5-[amino(sulfoamino)phosphinyl]-l-ornithyl-l-alanyl-n6-(aminoiminomethyl)-l-lysine |
phaseolotoxin |
C08440 , |
qyf9h833x4 , |
AKOS030531674 |
l-lysine, n5-(amino(sulfoamino)phosphinyl)-l-ornithyl-l-alanyl-n6-(aminoiminomethyl)- |
(2s)-2-((2s)-2-((2s)-2-amino-5-((amino(sulfoamino)phosphoryl)amino)pentanamido)propanamido)-6-guanidinohexanoicacid |
phaseolotoxin (PT) is a non-host specific phytotoxin produced by the plant pathogenic bacterium Pseudomonas syringae (P.S.) pv. PT is an effective inhibitor of ornithine carbamoyltransferase (OCTase) activity.
Excerpt | Reference | Relevance |
---|---|---|
"Phaseolotoxin is an effective inhibitor of ornithine carbamoyltransferase (OCTase) activity from plant, mammalian and bacterial sources and causes a phenotypic requirement for arginine." | ( Expression of the gene for resistance to phaseolotoxin (argK) depends on the activity of genes phtABC in Pseudomonas syringae pv. phaseolicola. Aguilera, S; Alvarez-Morales, A; Bravo, J; De la Torre-Zavala, S; Hernández-Flores, JL; Murillo, J, 2012) | 1.37 |
"Phaseolotoxin (PT) is a non-host specific phytotoxin produced by the plant pathogenic bacterium Pseudomonas syringae (P.s.) pv. " | ( Inhibitory effects of phaseolotoxin on proliferation of leukemia cells HL-60, K-562 and L1210 and pancreatic cells RIN-m5F. Bachmann, AS; Patil, SS; Ratnapala, L; Xu, R, 2004) | 2.08 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 10 (21.28) | 18.7374 |
1990's | 12 (25.53) | 18.2507 |
2000's | 14 (29.79) | 29.6817 |
2010's | 10 (21.28) | 24.3611 |
2020's | 1 (2.13) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.37) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (4.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 48 (96.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |